FOXP3 and plasma cell myeloma: At the same time, there were no differences in relative and absolute counts of PB CD4+FOXP3+ T cells between the patients without detectable levels (<0.01% of all nucleated BM cells) of myeloma PCs and the patients with minimal residual disease (Table 5).